Martha C Nason

List of Publications by Year
in descending order

96 papers	17,239 citations	36303 51 h-index	39675 94 g-index
104 all docs	104 docs citations	104 times ranked	20738 citing authors

#	Article	IF	Citations
1	HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood, 2006, 107, 4781-4789.	1.4	1,681
2	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.	12.6	1,600
3	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	27.8	1,153
4	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. Journal of Infectious Diseases, 2011, 203, 780-790.	4.0	957
5	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	27.0	936
6	SPICE: Exploration and analysis of post‐cytometric complex multivariate datasets. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 167-174.	1.5	799
7	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science, 2013, 341, 1359-1365.	12.6	686
8	Durability of mRNA-1273 vaccine‐induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	12.6	459
9	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. New England Journal of Medicine, 2021, 385, 2348-2360.	27.0	458
10	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature, 2014, 511, 601-605.	27.8	422
11	Rapid development of a DNA vaccine for Zika virus. Science, 2016, 354, 237-240.	12.6	348
12	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	30.7	313
13	Prefusion F‐specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science Translational Medicine, 2015, 7, 309ra162.	12.4	312
14	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature, 2014, 514, 642-645.	27.8	308
15	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. Journal of Virology, 2010, 84, 1631-1636.	3.4	304
16	Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies. Journal of Virology, 2009, 83, 188-199.	3.4	297
17	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Journal of Experimental Medicine, 2014, 211, 2061-2074.	8.5	297
18	Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control. PLoS Pathogens, 2010, 6, e1000917.	4.7	284

#	Article	IF	Citations
19	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature, 2016, 533, 105-109.	27.8	281
20	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody *In Vitro* Improves Protection against Lentiviral Infection *In Vivo*. Journal of Virology, 2014, 88, 12669-12682.	3.4	248
21	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299.	12.6	244
22	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Science Translational Medicine, 2014, 6, 243ra88.	12.4	222
23	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science, 2013, 340, 751-756.	12.6	213
24	A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.	12.6	207
25	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2711-2716.	7.1	201
26	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. New England Journal of Medicine, 2017, 377, 1438-1447.	27.0	199
27	Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood, 2011, 117, 4805-4815.	1.4	193
28	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell, 2022, 185, 1556-1571.e18.	28.9	179
29	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. Journal of Infectious Diseases, 2007, 196, 1732-1740.	4.0	175
30	Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. Journal of Experimental Medicine, 2009, 206, 923-936.	8.5	140
31	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2014, 505, 502-508.	27.8	140
32	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. Journal of Infectious Diseases, 2011, 203, 1396-1404.	4.0	138
33	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine, 2007, 25, 4085-4092.	3.8	134
34	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. PLoS ONE, 2010, 5, e9015.	2.5	125
35	HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies. Journal of Virology, 2015, 89, 4201-4213.	3.4	121
36	Regulatory T Cells Promote Early Influx of CD8+ T Cells in the Lungs of Respiratory Syncytial Virus-Infected Mice and Diminish Immunodominance Disparities. Journal of Virology, 2009, 83, 3019-3028.	3.4	120

#	Article	IF	Citations
37	Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. Journal of Allergy and Clinical Immunology, 2019, 143, 1482-1495.	2.9	116
38	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. Immunity, 2018, 49, 301-311.e5.	14.3	110
39	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet, The, 2019, 393, 889-898.	13.7	99
40	Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts. Toxicological Sciences, 2006, 91, 610-619.	3.1	94
41	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Annals of Internal Medicine, 2021, 174, 221-228.	3.9	86
42	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates. Science, 2021, 374, 1343-1353.	12.6	83
43	Comparative Efficacy of Hemagglutinin, Nucleoprotein, and Matrix 2 Protein Gene-Based Vaccination against H5N1 Influenza in Mouse and Ferret. PLoS ONE, 2010, 5, e9812.	2.5	72
44	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. Journal of Virology, 2012, 86, 3393-3397.	3.4	71
45	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. PLoS ONE, 2013, 8, e59340.	2.5	71
46	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Journal of Virology, 2016, 90, 1321-1332.	3.4	68
47	Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature, 2021, 595, 289-294.	27.8	68
48	Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them. New England Journal of Medicine, 2021, 384, e2.	27.0	66
49	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	28.9	64
50	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. Clinical Trials, 2016, 13, 49-56.	1.6	63
51	Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses. Clinical Nuclear Medicine, 2017, 42, 329-334.	1.3	63
52	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. New England Journal of Medicine, 2020, 382, 1366-1369.	27.0	63
53	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. Journal of Virology, 2010, 84, 630-638.	3.4	57
54	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology, 2021, 22, 1306-1315.	14.5	57

#	Article	IF	Citations
55	Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. Human Vaccines and Immunotherapeutics, 2014, 10, 3446-3454.	3.3	50
56	Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vectored Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer's Construct, or Gene Inserts. Journal of Immunotoxicology, 2008, 5, 315-335.	1.7	49
57	Multivalent HA DNA Vaccination Protects against Highly Pathogenic H5N1 Avian Influenza Infection in Chickens and Mice. PLoS ONE, 2008, 3, e2432.	2.5	46
58	Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia. Clinical Infectious Diseases, 2020, 71, 652-660.	5.8	44
59	Design of vaccine efficacy trials during public health emergencies. Science Translational Medicine, 2019, 11, .	12.4	41
60	Neutralizing Antibody Titers Conferring Protection to Macaques from a Simian/Human Immunodeficiency Virus Challenge Using the TZM-bl Assay. AIDS Research and Human Retroviruses, 2010, 26, 89-98.	1.1	40
61	Likelihood-Based Data Squashing: A Modeling Approach to Instance Construction. Data Mining and Knowledge Discovery, 2002, 6, 173-190.	3.7	39
62	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine,the, 2021, 9, 1111-1120.	10.7	38
63	Virus Inhibition Activity of Effector Memory CD8$^+$ T Cells Determines Simian Immunodeficiency Virus Load in Vaccinated Monkeys after Vaccine Breakthrough Infection. Journal of Virology, 2012, 86, 5877-5884.	3.4	37
64	Design and Analysis of Crossover Trials for Absorbing Binary Endpoints. Biometrics, 2010, 66, 958-965.	1.4	33
65	Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication. PLoS Pathogens, 2018, 14, e1007246.	4.7	33
66	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	12.4	30
67	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. Clinical Infectious Diseases, 2021, 73, 1849-1856.	5.8	24
68	Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011). PLoS ONE, 2014, 9, e91366.	2.5	23
69	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS ONE, 2015, 10, e0136626.	2.5	23
70	Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination. PLoS ONE, 2012, 7, e33969.	2.5	22
71	COVID-19 vaccine trials: The use of active controls and non-inferiority studies. Clinical Trials, 2021, 18, 335-342.	1.6	22
72	Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. Clinical Infectious Diseases, 2017, 65, 1308-1315.	5.8	20

#	Article	IF	Citations
73	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. Lancet HIV,the, 2019, 6, e475-e482.	4.7	19
74	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Annals of Internal Medicine, 2021, 174, 1118-1125.	3.9	15
75	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). PLoS ONE, 2016, 11, e0166393.	2.5	14
76	A High Viral Burden Predicts the Loss of CD8 T-Cell Responses Specific for Subdominant Gag Epitopes during Chronic Human Immunodeficiency Virus Infection. Journal of Virology, 2007, 81, 13809-13815.	3.4	13
77	Conditioning in 2 Ã— 2 Tables. Biometrics, 2009, 65, 316-322.	1.4	13
78	Early immunologic and virologic predictors of clinical HIV-1 disease progression. Aids, 2013, 27, 697-706.	2.2	13
79	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine, 2022, 48, 101477.	7.1	13
80	Statistics and logistics: Design of Ebola vaccine trials in West Africa. Clinical Trials, 2016, 13, 87-91.	1.6	11
81	Effects of Lymphocyte Isolation and Timing of Processing on Detection of CD127 Expression on T Cells in Human Immunodeficiency Virus-Infected Patients. Vaccine Journal, 2005, 12, 228-230.	3.1	10
82	Patterns of signs, symptoms, and laboratory values associated with Zika, dengue, and undefined acute illnesses in a dengue endemic region: Secondary analysis of a prospective cohort study in southern Mexico. International Journal of Infectious Diseases, 2020, 98, 241-249.	3.3	8
83	CARTscans: A Tool for Visualizing Complex Models. Journal of Computational and Graphical Statistics, 2004, 13, 807-825.	1.7	8
84	Adjustment for Disease Severity in the Test-Negative Study Design. American Journal of Epidemiology, 2021, 190, 1882-1889.	3.4	6
85	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. Aids, 2021, 35, 1567-1574.	2.2	6
86	Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial. PLoS ONE, 2014, 9, e106240.	2.5	5
87	A boundaryâ€optimized rejection region test for the twoâ€sample binomial problem. Statistics in Medicine, 2018, 37, 1047-1058.	1.6	5
88	COVID-19 vaccine trials: The potential for â€œhybridâ€analyses. Clinical Trials, 2021, 18, 391-397.	1.6	4
89	Adaptive Viral Load Monitoring Frequency to Facilitate Differentiated Care: A Modeling Study From Rakai, Uganda. Clinical Infectious Diseases, 2020, 71, 1017-1021.	5.8	3
90	Susceptibility to SIV Infection After Adenoviral Vaccination in a Low Dose Rhesus Macaque Challenge Model. Pathogens and Immunity, 2019, 4, 1.	3.1	3

#	Article	IF	Citations
91	A Note on Correction of Information Time in a Survival Trial Using an Alpha Spending Function. Statistics in Biosciences, 2011, 3, 250-259.	1.2	2
92	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains. Journal of Infectious Diseases, 2020, 221, 756-765.	4.0	2
93	The mechanistic analysis of founder virus data inÂchallenge models. Statistics in Medicine, 2021, 40, 4492-4504.	1.6	2
94	An Augmented Probit Model for Missing Predictable Covariates in Quantal Bioassay with Small Sample Size. Biometrics, 2011, 67, 1127-1134.	1.4	1
95	Response to letter by Antonio MartÃn AndrÃ©s on â€œA boundaryâ€optimized rejection region test for the twoâ€sample binomial problemâ€. Statistics in Medicine, 2018, 37, 2303-2306.	1.6	0
96	Cardiovascular Biomarker Profile on Antiretroviral Therapy Is Not Influenced by History of an IRIS Event in People With HIV and Suppressed Viremia. Open Forum Infectious Diseases, 2020, 7, ofaa017.	0.9	0